A new type of immune-based therapy has recently been discovered by Viral Genetics, Inc. This biotechnology company is located in San Marino, California with a mission to discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound (TNP), which may help Lyme disease.
With a commitment to discovering and developing immune-based therapies for HIV and AIDS using its thymus nuclear protein compound (TNP), Viral Genetics’ new model was initially proposed solely for HIV/AIDS. However by unraveling the mechanism of TNP, Dr. Newell, a Professor at Dartmouth University and Advisor to Viral Genetics, has identified its potential promise for several diseases including Lyme disease. Thankfully, further studies on Lyme disease are being conducted thanks to a grant earmarked specifically for Lyme disease.
“We’ve always theorized that TNP could serve as a pathway to more answers and, potentially aid in the development of more effective treatments for a variety of immune based diseases, but this is our first study outside of the HIV/AIDS arena, so we are encouraged by TNP’s application to Lyme. We look forward to what further research could yield,” added Newell.
The study team made progress using basic academic research to understand molecular mechanisms that account for whether or not a person contracts Lyme Disease subsequent to the tick bite. The team is now transitioning quickly to clinical research.
“The initial data is promising and our mission is to continue making further progress in our effort to unravel the extreme complexities behind Lyme Disease.” said Monica Ord, SVP of corporate development and communications.”
Some researchers contend Lyme is driven by chronic infection and recommend patients be treated with antibiotics for the long term. Others support the hypothesis that the disease is the result of autoimmune T cell activation that occurs subsequent to the initial infection or after the infection has cleared.
However, as most of us know, Lyme disease easily evade the immune system of its human host by altering its genetic code, altering its structure from one type of cell to another and hiding within white blood cells (to name just a few evasion methods.)
“Our model reconciles both the initial disease and accounts for the consequent processes that appear pathologically similar to autoimmune disease,” said Dr. Newell.
Until these scientific truths are brought forward and quickly researched collaboratively, the patients who wait daily for answers to their suffering are the victims. Our deep hope is to make a difference in their lives,” said Monica Ord, SVP of corporate development and communications, Viral Genetics, Inc.
According to “MarketWatch” News, Viral Genetics has been invited to participate in the ILADS 2008 Scientific Studies.
ILADS, an international nonprofit and multidisciplinary medical society, is dedicated to the diagnosis and appropriate treatment of Lyme and its associated diseases. The 2008 ILADS Scientific Session will take place in San Francisco on Lyme disease in the U.S. Lyme Disease Resource will be reporting on the event.